Stocky turns companies like CME into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Hold. CME's diversified derivatives platform generates steady cash flows (61 Value score) and moderate growth (54 Growth score), but a forward P/E of 21.1× limits margin of safety. Leadership alignment is middling (59.5), and the core vulnerability—reliance on financial buffers without structural moat breadth—means downside protection depends more on execution than competitive positioning. Suitable for patient holders; not yet compelling for new positions.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for CME:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 62/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates CME (CME) at 62/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Hold. CME's diversified derivatives platform generates steady cash flows (61 Value score) and moderate growth (54 Growth score), but a forward P/E of 21.1× limits margin of safety. Leadership alignment is middling (59.5), and the core v
CME's current Stocky Verdict is 62/100, placing it in the "Hold" band. This composite combines a 61/100 Compounder score, 60/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for CME yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
CME scores 60/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
CME's Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to CME.
Sign up free and unlock the full analysis on CME — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for CME in the app.
